Sichenzia Ross Friedman Ference LLP Advises Sorrento Therapeutics, Inc. on $25.0 million Public Offering of Common Stock
NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, in a $25.0 million public offering. The offering consists of 4,765,000 shares of common stock priced at $5.25 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Jeff Fessler and Marcelle Balcombe.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Represents Aegis Capital Corp. in $2.7 Million Registered Direct Offering - November 18, 2017
- Sichenzia Ross Ference Kesner LLP Represents CloudCommerce, Inc., in Acquisition of WebTegrity, LLC - November 18, 2017
- Sichenzia Ross Ference Kesner LLP Represents MabVax Therapeutics Holdings, Inc. in $5 Million Registered Direct Offerings - November 15, 2017